Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

NCT02365662 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02365662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02365662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
January 9, 2015
Completion date
March 15, 2018
Enrollment
46 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, non-small cell lung cancer, triple negative breast cancer